U.S. AI-Enabled Neurology Devices Market: USD 15.08B

Market Outlook

By 2035, the U.S. AI-Enabled Neurology Devices Market is expected to reach approximately USD 15.08 billion, expanding at a CAGR of 18.51% during the forecast period 2026–2035. The market was valued at USD 2.76 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions. The market estimate represents revenue generated by regulated medical devices and device-associated software in which artificial intelligence materially supports neurological detection, classification, monitoring, treatment personalization, navigation, intervention, or rehabilitation. It excludes general-purpose hospital analytics, non-medical consumer wellness applications, and conventional neurology devices without an AI-enabled function.

The U.S. AI-enabled neurology devices industry is developing at the intersection of neuroscience, medical imaging, biosignal analytics, connected monitoring, implantable therapy, and hospital workflow automation. Demand is supported by the scale and urgency of neurological disease in the United States. More than 795,000 people experience a stroke each year, approximately 2.9 million adults live with active epilepsy, an estimated 7.2 million Americans aged 65 and older were living with Alzheimer’s disease in 2025, and about 1.2 million people are now affected by Parkinson’s disease or atypical parkinsonisms. These conditions create a large addressable need for tools that detect deterioration earlier, prioritize time-sensitive cases, interpret complex EEG and imaging data, personalize stimulation, and extend neurological surveillance beyond specialist centers.

The market is moving beyond first-generation image triage algorithms toward multimodal and workflow-embedded device platforms. High-growth areas include AI-assisted stroke detection and transfer coordination, automated EEG interpretation, wearable seizure monitoring, predictive dementia assessment, closed-loop tremor therapy, adaptive deep brain stimulation, robotic and image-guided neurosurgery, neurocritical care surveillance, and sensor-based digital biomarkers for movement and cognitive disorders. The commercial value is increasingly captured through a combination of capital equipment, annual software licenses, per-study fees, connected-device subscriptions, disposable components, service contracts, and enterprise deployment across multi-hospital networks.

Historical market expansion accelerated from USD 1.27 billion in 2021 to USD 1.51 billion in 2022, USD 1.83 billion in 2023, and USD 2.24 billion in 2024 before reaching USD 2.76 billion in 2025. Growth during this period was supported by post-pandemic normalization of stroke and neurosurgical volumes, broader cloud deployment in radiology, rising use of rapid EEG in intensive care, increasing acceptance of wearable neurological monitoring, and a larger pipeline of FDA-authorized AI-enabled devices. The historical CAGR of approximately 21.4% reflects a market moving from pilot programs toward scaled clinical deployment, although future growth will be moderated by procurement scrutiny, interoperability requirements, evidence expectations, cybersecurity obligations, and variable reimbursement.

Introduction

According to the U.S. AI-Enabled Neurology Devices Market Report, the market is shaped by a rare combination of high neurological disease burden, advanced imaging infrastructure, major academic neuroscience centers, mature stroke networks, large integrated delivery systems, and a rapidly expanding digital health ecosystem. Neurological care is especially suitable for AI-enabled devices because clinicians must interpret large volumes of time-sensitive and highly dimensional information. Brain CT and MRI studies, angiography, EEG waveforms, intracranial pressure data, movement signals, speech patterns, gait measurements, cognitive testing, and implant telemetry all generate datasets that can exceed the practical review capacity of limited specialist teams.

The market is not a single software category. It includes AI-enabled diagnostic imaging systems, stroke and neurovascular triage software, portable and continuous EEG devices, seizure detection wearables, neuromodulation systems, neuroprosthetic control platforms, surgical navigation systems, neurointerventional robotics, digital cognitive assessment tools, and connected rehabilitation devices. Some products are sold as standalone software as a medical device, while others are embedded in imaging scanners, monitoring hardware, wearable sensors, implant programmers, robotic platforms, or neurosurgical navigation systems. This mix creates both recurring software revenue and hardware-linked replacement cycles.

The U.S. clinical infrastructure provides a substantial installed base for adoption. The country has more than 6,000 hospitals, more than 900,000 staffed beds, over 32 million annual community-hospital admissions, hundreds of certified stroke centers, and a dense network of academic neurology, neurosurgery, neurocritical care, epilepsy, sleep, and rehabilitation programs. However, access remains uneven. Rural hospitals and smaller community facilities often lack around-the-clock neuroradiology, neurophysiology, or vascular neurology coverage. AI-enabled devices are therefore evaluated not only as diagnostic tools but also as mechanisms to extend specialist capacity, standardize care, reduce unnecessary transfers, and improve time-to-treatment across distributed networks.

Hospital procurement behavior is central to market development. U.S. buyers increasingly require more than algorithm accuracy. Value analysis committees assess sensitivity and specificity in the intended population, false-positive burden, alert routing, cybersecurity, data governance, model-update controls, interoperability with PACS and electronic health records, physician adoption, implementation labor, and measurable impact on clinical throughput. A device that performs well in a retrospective study may still fail commercially if it creates alert fatigue, requires excessive workflow redesign, or cannot document economic benefit. The strongest products are those that fit naturally into care pathways and create evidence across both clinical and operational outcomes.

From 2026 to 2035, the defining strategic shift will be from isolated AI point solutions to longitudinal neurological care platforms. Health systems will favor solutions that connect early detection, diagnostic confirmation, treatment selection, procedure guidance, remote monitoring, and outcomes documentation. Manufacturers that combine devices, software, clinical evidence, reimbursement support, and enterprise integration will be better positioned than companies offering a single algorithm without workflow ownership. The market will also become more selective as providers consolidate vendors and demand proof that AI improves care delivery rather than simply adding another digital layer.

Key Market Drivers: What’s Fueling the U.S. AI-Enabled Neurology Devices Market Boom?

The first major driver is the scale and economic burden of neurological disease. Stroke remains one of the most time-sensitive conditions in U.S. medicine, with more than 795,000 events annually and one stroke occurring approximately every 40 seconds. Alzheimer’s disease and related dementias generated projected health and long-term care costs of about USD 384 billion in 2025, excluding the value of unpaid caregiving. Parkinson’s disease and atypical parkinsonisms generated an estimated USD 82.2 billion in total U.S. costs in 2024. Epilepsy affects millions of adults and children and creates recurring costs from emergency visits, uncontrolled seizures, medication management, diagnostic testing, and injury risk. These burdens make earlier detection and more scalable monitoring economically relevant to payers and providers.

A second driver is the shortage and uneven distribution of neurological expertise. Neurologists, epileptologists, neurophysiologists, neuroradiologists, movement-disorder specialists, and neurocritical care clinicians are concentrated in large metropolitan and academic centers. Smaller hospitals may have imaging equipment and emergency capacity but limited specialist coverage during nights and weekends. AI-enabled stroke triage, rapid EEG, automated seizure burden analysis, remote neurological monitoring, and cloud-based image interpretation can help prioritize cases and direct limited specialist attention. The value proposition is strongest when the technology reduces clinically meaningful delays rather than merely producing an additional score.

A third driver is the economics of time-sensitive stroke and neurocritical care. In acute ischemic stroke, intracranial hemorrhage, large-vessel occlusion, hydrocephalus, nonconvulsive status epilepticus, and traumatic brain injury, delays can increase disability, length of stay, transfer cost, intensive care utilization, and downstream rehabilitation burden. AI-enabled devices that shorten image-to-notification time, accelerate stroke-team activation, identify seizures without waiting for conventional EEG availability, or improve neurocritical monitoring can influence the total cost of an episode. This creates a stronger purchasing case than applications where the clinical consequence of delay is less immediate.

A fourth driver is the rapid expansion of connected neurological monitoring outside the hospital. Wearable seizure devices, wrist-based tremor sensors, gait and mobility monitoring, speech analysis, sleep and EEG systems, and app-connected neurostimulation devices are creating longitudinal datasets that were previously unavailable. These devices can support symptom tracking, medication titration, adverse-event detection, therapy response assessment, and caregiver notification. Home monitoring is particularly important for epilepsy, Parkinson’s disease, essential tremor, multiple sclerosis, post-stroke rehabilitation, and cognitive decline because office visits provide only a limited view of variable day-to-day function.

A fifth driver is the maturation of neuromodulation and closed-loop therapy. Conventional deep brain stimulation, vagus nerve stimulation, responsive neurostimulation, transcranial magnetic stimulation, and peripheral nerve stimulation have established the clinical value of device-based neurological therapy. AI and adaptive algorithms are extending this market by using physiologic or behavioral signals to modify stimulation parameters, detect symptom states, and personalize treatment. Closed-loop systems can improve battery efficiency, reduce programming burden, and potentially deliver more consistent symptom control. This shifts competition from hardware specifications toward sensing quality, algorithm performance, programming workflow, and long-term data services.

A sixth driver is the expanding U.S. regulatory pipeline. The latest FDA AI-enabled medical device dataset reviewed for this report contained 1,524 authorized devices across medical specialties, including 70 entries under the neurology lead panel. Neurology remains smaller than radiology by device count, but its portfolio is becoming more diverse. Recent authorizations include predictive cognitive assessment, machine-learning EEG analysis, wearable seizure monitoring, closed-loop tremor stimulation, delirium monitoring, and AI-enabled surgical navigation. This diversification signals that commercial opportunity is moving beyond brain imaging into active monitoring and therapy.

A seventh driver is hospital capital planning around neuroscience service lines. Comprehensive stroke centers, epilepsy monitoring units, neurocritical care units, movement-disorder programs, and neurosurgical centers use advanced technology to attract referrals and retain complex patients. AI-enabled devices can strengthen service-line differentiation when they improve transfer capture, procedural precision, bed utilization, or specialist productivity. Procurement is therefore often linked to broader strategic priorities such as stroke certification, teleneurology expansion, operating-room modernization, ambulatory neurology growth, and enterprise digital transformation.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. AI-enabled neurology devices market is increasingly focused on multimodal intelligence, clinically meaningful automation, adaptive therapy, and deployability across real-world workflows. The next phase of competition will not be defined by whether a device uses AI. It will be defined by whether the AI can operate reliably across diverse patient populations, scanner types, care settings, and data-quality conditions while preserving clinician oversight. Manufacturers are therefore investing in prospective validation, human-factors engineering, model monitoring, cybersecurity, and integration rather than treating algorithm development as the only source of differentiation.

AI-enabled neuroimaging is moving from abnormality detection toward orchestration of the entire acute-care pathway. Stroke platforms can identify suspected large-vessel occlusion, intracranial hemorrhage, perfusion mismatch, aneurysm, and other urgent findings, then route alerts to stroke teams and transfer centers. The commercial advantage increasingly comes from communication, case tracking, image access, and network coordination rather than image classification alone. Health systems want platforms that reduce fragmented phone calls, create a shared clinical timeline, and support regional referral management across emergency departments, radiology, neurology, neurointervention, and transport services.

EEG innovation is becoming a major growth engine. Traditional EEG can be slow to initiate and difficult to interpret in hospitals without continuous neurophysiology coverage. Portable headbands, rapid-application electrodes, cloud review, automated seizure detection, seizure-burden trending, delirium assessment, and machine-learning waveform analysis are reducing the operational barriers to neurological monitoring. These technologies are particularly relevant in intensive care, emergency medicine, post-cardiac arrest care, and suspected nonconvulsive seizures. Successful systems are designed to augment expert interpretation while enabling earlier action by non-specialist teams.

Closed-loop neuromodulation is raising the bar in movement disorders and epilepsy. AI-enabled tremor devices can use embedded sensors to estimate symptom severity and adjust stimulation while the device is worn. Responsive neurostimulation can detect abnormal electrical patterns and deliver therapy based on individualized signals. Deep brain stimulation platforms are evolving toward adaptive programming informed by biomarkers, patient state, and real-world symptom data. Over the forecast period, the market will increasingly reward systems that combine implant or wearable hardware with sensing, algorithmic control, remote programming, and clinician dashboards.

Digital biomarkers are opening new commercial pathways in neurodegenerative disease. Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and other progressive disorders fluctuate across motor, cognitive, speech, sleep, and behavioral domains. Smartphone tasks, wearables, home sensors, instrumented gait analysis, voice analytics, eye tracking, and connected assessment devices can capture changes more frequently than clinic-based scales. The strategic opportunity is not only diagnosis. It includes clinical trial enrichment, therapy-response measurement, progression forecasting, and risk-based follow-up. Devices that produce reproducible endpoints may become valuable to both healthcare providers and life-science companies.

AI-assisted neurosurgery and neurointervention are also expanding. Surgical navigation platforms increasingly automate image registration, segmentation, trajectory planning, anatomical mapping, and instrument localization. Neurointerventional systems use advanced imaging and decision support to improve planning for thrombectomy, aneurysm treatment, and other complex procedures. Robotics and augmented visualization can support precision while reducing cognitive load, but adoption depends on operating-room reliability, surgeon trust, capital economics, and service support. Hospitals will favor systems that integrate with existing imaging and navigation infrastructure rather than requiring isolated workflows.

Manufacturers are also raising the bar through lifecycle governance. AI-enabled devices may encounter performance drift as clinical practices, scanners, protocols, patient populations, and data distributions change. U.S. buyers are becoming more attentive to predetermined change controls, version transparency, validation after software updates, local performance monitoring, and clear responsibility for incident investigation. Companies that can explain how models are trained, updated, audited, and secured will have an advantage in enterprise contracting, especially when devices operate across multiple facilities or influence time-critical decisions.

Segmentation Insights

The U.S. AI-Enabled Neurology Devices Market is segmented on the basis of product type, application, end user, technology type, and region.

By Product Type

AI-enabled neuroimaging and stroke-triage systems represent the largest product category, accounting for an estimated one-third of 2025 market revenue. This segment includes CT and MRI interpretation software, large-vessel occlusion detection, intracranial hemorrhage detection, perfusion analysis, automated image reconstruction, quantitative brain volumetry, dementia-risk assessment, and workflow communication platforms. Demand is supported by the installed base of imaging equipment and the urgency of stroke care. Competitive differentiation is shifting toward enterprise interoperability, cross-site deployment, alert precision, transfer coordination, and support for multiple neurovascular conditions within one platform.
AI-enabled EEG and seizure-monitoring devices form a rapidly expanding category. The segment includes portable EEG systems, rapid-application headbands, automated seizure detection, seizure-burden trending, cloud-based EEG review, delirium monitoring, sleep-stage analysis, wearable convulsive-seizure detection, and caregiver alert systems. Growth is supported by the high number of patients with epilepsy, under-recognition of nonconvulsive seizures in critical care, and limited neurophysiology staffing. Recurring revenue is generated through sensors, headbands, subscriptions, cloud review, monitoring services, and replacement wearables.
Intelligent neuromodulation and implantable neurological devices represent a high-value product segment. It includes adaptive deep brain stimulation, responsive neurostimulation, AI-assisted vagus nerve stimulation, closed-loop tremor stimulation, implant programmers, sensing-enabled stimulators, and software used to optimize therapy. The segment benefits from premium device pricing, long patient lifecycles, replacement demand, and recurring programming requirements. Growth will depend on evidence that adaptive therapy improves outcomes, reduces clinician programming time, and supports remote or data-guided follow-up.
AI-assisted surgical navigation and neurointerventional systems include stereotactic navigation, automated image registration, robotic planning, cranial trajectory guidance, intraoperative visualization, neurovascular procedure support, and AI-enabled thrombectomy workflow. These products are purchased primarily by tertiary hospitals and neuroscience centers. Revenue is concentrated in capital equipment, software upgrades, disposable instruments, and service contracts. Adoption is strongly influenced by surgeon preference, installed-base compatibility, operating-room efficiency, and the ability to support multiple procedure types.
Wearable, digital biomarker, and neurorehabilitation devices represent a smaller but high-growth category. This segment includes gait sensors, movement monitors, tremor wearables, eye-tracking systems, digital cognitive assessments, speech and motor analysis tools, brain-computer interface systems, robotic rehabilitation devices, and sensor-enabled home therapy. The addressable opportunity is broad because these products can support chronic disease management, clinical trials, rehabilitation, and caregiver engagement. Commercial success depends on sustained patient adherence, clinically interpretable outputs, and integration into reimbursable care pathways.

By Application

Stroke and cerebrovascular disease management is the dominant application segment. AI-enabled devices support large-vessel occlusion identification, hemorrhage detection, perfusion analysis, transfer decisions, stroke-team communication, post-procedure imaging, and rehabilitation. More than 795,000 U.S. strokes annually create a large recurring diagnostic and care-coordination need. The application is commercially attractive because minutes can influence eligibility for thrombectomy or thrombolysis, disability outcomes, transfer economics, and length of stay. Health systems increasingly evaluate stroke AI at the network level rather than as a single-hospital radiology tool.
Epilepsy and seizure management is one of the fastest-growing applications. Devices are used for ambulatory seizure detection, inpatient EEG surveillance, intensive-care seizure burden assessment, caregiver alerts, and closed-loop therapy. Approximately 2.9 million U.S. adults live with active epilepsy, and many patients continue to experience uncontrolled seizures. Growth is supported by demand for home monitoring, earlier identification of nonconvulsive seizures, and better documentation of seizure frequency. The application also supports recurring device revenue through wearables, electrodes, cloud platforms, and long-term monitoring services.
Neurodegenerative disease applications include Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and related conditions. AI-enabled devices can quantify brain structure, analyze movement and speech, assess cognition, track sleep and autonomic signals, and identify changes between clinic visits. The large and aging U.S. patient population creates substantial long-term opportunity, but adoption requires careful clinical validation because disease progression is slow and heterogeneous. The strongest near-term use cases are risk stratification, progression monitoring, clinical trial support, therapy-response measurement, and prioritization of patients for specialist evaluation.
Movement disorders and tremor management include essential tremor, Parkinsonian symptoms, dystonia, and gait impairment. AI-enabled stimulation devices, wearable accelerometers, digital motor assessments, and adaptive programming tools can quantify symptom severity and personalize therapy. This application is moving from subjective episodic scoring toward continuous measurement in real-world environments. Growth will be driven by closed-loop wearables, sensing-enabled implants, remote programming, and increased use of objective digital endpoints in clinical care and research.
Neurosurgery, brain injury, neurocritical care, and rehabilitation represent a diverse application segment. AI-enabled devices support cranial navigation, tumor and lesion planning, hydrocephalus procedures, intracranial monitoring, traumatic brain injury assessment, delirium screening, post-operative surveillance, and motor rehabilitation. More than 69,000 TBI-related deaths were recorded in the United States in 2021, and millions of injury-related emergency visits occur annually. The addressable market is strengthened by the need to standardize complex care, reduce complications, and extend specialized neurological monitoring to emergency and intensive-care settings.

By End User

Hospitals and integrated health systems are the dominant end users, accounting for the majority of market value. They purchase stroke-triage platforms, imaging software, EEG systems, neuromodulation devices, surgical navigation, neurointerventional equipment, and ICU monitoring solutions. Large systems increasingly negotiate enterprise agreements across multiple facilities and evaluate whether a platform can support community hospitals, referral centers, and tertiary neuroscience hubs. Their purchasing decisions influence vendor scale, pricing, implementation standards, and long-term market access.
Comprehensive stroke centers, neuroscience institutes, and academic medical centers are strategically important early adopters. These institutions manage high-acuity cases, participate in clinical trials, generate evidence, train specialists, and influence national practice patterns. They are most likely to adopt predictive imaging, advanced EEG analytics, adaptive stimulation, brain-computer interfaces, robotic navigation, and digital biomarkers. However, their procurement processes are demanding and usually require strong clinical validation, research collaboration, cybersecurity review, and integration with existing data infrastructure.
Neurology practices, epilepsy centers, sleep laboratories, and diagnostic clinics are growing end users for ambulatory EEG, digital cognitive assessment, movement monitoring, wearable seizure detection, and connected neurostimulation follow-up. These buyers prioritize ease of use, reliable reimbursement support, low implementation burden, and clear clinical actionability. They are less able than large hospitals to absorb complex integration costs, creating demand for cloud-based systems that can be deployed with limited information-technology resources.
Ambulatory surgery centers and specialized neurosurgical facilities are emerging end users for selected navigation, robotic, and neuromodulation procedures. High-acuity cranial and neurovascular interventions remain hospital centered, but some spine, pain, stimulation, and diagnostic procedures are migrating to outpatient settings. Devices designed for these environments must have compact footprints, predictable procedure economics, rapid setup, and service models aligned with lower overhead. Capital-light leasing and per-procedure pricing may accelerate adoption.
Home healthcare, rehabilitation providers, caregivers, and remote monitoring programs represent the fastest-growing end-user group. Wearable seizure systems, tremor devices, gait monitors, digital therapy platforms, and connected rehabilitation tools move neurological measurement into daily life. Their value depends on patient adherence, caregiver usability, secure data transmission, and escalation protocols that avoid unnecessary alarms. Manufacturers that combine simple hardware with clinically managed services may be better positioned than those relying on passive consumer engagement alone.

By Technology Type

Machine learning and deep learning dominate current device development. These methods are used for image classification, lesion detection, segmentation, brain volumetry, EEG interpretation, seizure detection, signal denoising, and outcome prediction. Deep learning is especially important in neuroimaging because it can process complex spatial patterns across CT and MRI. The commercial challenge is to maintain performance across scanners, protocols, institutions, and patient populations while providing enough transparency for clinical adoption and regulatory review.
Computer vision and advanced image processing form the core technology layer for stroke, neurosurgery, neurointervention, and cognitive imaging applications. Algorithms can identify vascular occlusion, hemorrhage, ischemic change, anatomical structures, surgical landmarks, and changes in brain volume. Future systems will increasingly combine detection with procedural planning and longitudinal comparison. Buyers will favor platforms that integrate with existing PACS, support multiple vendors, and minimize manual image transfer or workflow interruption.
Predictive analytics and multimodal biosignal processing are gaining importance. These technologies combine EEG, accelerometry, electrodermal activity, speech, gait, sleep, cognition, imaging, and clinical data to estimate risk or detect changes. Multimodal systems may outperform single-signal devices in complex neurological conditions, but they also create greater validation and interoperability requirements. The strongest commercial opportunities are likely to emerge where the model output leads to a clear action such as activating a stroke pathway, adjusting stimulation, escalating monitoring, or scheduling specialist review.
Closed-loop and adaptive intelligence is the fastest-growing technology type. It uses real-time sensor input to modify stimulation, alert thresholds, monitoring intensity, or therapy recommendations. Applications include responsive neurostimulation, adaptive deep brain stimulation, tremor control, seizure detection, and rehabilitation feedback. This technology can create a durable competitive moat because performance depends on the integration of sensors, hardware, algorithms, and clinical programming. It also raises higher expectations for safety, fail-safe behavior, update control, and post-market monitoring.
Cloud, edge, and hybrid deployment architectures determine how AI-enabled neurological devices fit into clinical operations. Cloud platforms support enterprise scaling, remote review, model updates, and cross-site coordination. Edge processing is important when latency, connectivity, privacy, or device autonomy is critical, as in wearables, implants, operating rooms, and emergency care. Hybrid models are becoming standard because they combine local acquisition and immediate inference with cloud analytics, longitudinal storage, and clinician dashboards. Procurement decisions increasingly consider architecture as part of resilience and cybersecurity planning.

Regional Insights: Where the Market is Growing Fastest

The U.S. AI-Enabled Neurology Devices Market is geographically segmented into the Northeast, Midwest, South, and West. Regional performance differs according to population age, stroke and chronic disease burden, density of academic medical centers, availability of neurologists, certified stroke infrastructure, medtech innovation, payer mix, rural access challenges, and willingness to invest in enterprise digital platforms. The West represented the largest regional market in 2025, while the South is expected to generate the greatest absolute expansion through 2035 because of population growth, aging, disease burden, and health-system investment. The Northeast remains the highest-acuity evidence-generating region, and the Midwest provides a stable base for neuromodulation, imaging, and integrated delivery-network adoption.

West

The West accounted for an estimated USD 0.82 billion in 2025 and is projected to reach approximately USD 4.81 billion by 2035, representing a regional CAGR of about 19.35%. The region includes California, Washington, Oregon, Nevada, Arizona, New Mexico, Colorado, Utah, Idaho, Montana, Wyoming, Alaska, and Hawaii. Its leadership is supported by a large technology ecosystem, strong venture funding, major academic medical centers, large integrated health systems, and early adoption of cloud imaging, digital biomarkers, wearables, robotics, and connected care.

California is the largest state market in the region and the most strategically important U.S. innovation hub for AI-enabled neurology devices. The state combines major neuroscience programs, high stroke and dementia burden, extensive imaging infrastructure, and a concentration of software, semiconductor, digital health, and medtech talent. Health systems in the San Francisco Bay Area, Los Angeles, San Diego, Sacramento, and Orange County are important early evaluators of stroke AI, EEG analytics, neurosurgical navigation, and remote neurological monitoring. California also provides access to clinical research partners and venture capital, although procurement cycles can be rigorous and cybersecurity requirements are demanding.

Washington, Oregon, Colorado, and Utah are attractive markets for enterprise deployment. These states have strong integrated delivery networks and digitally mature provider organizations that can scale platforms across urban and regional hospitals. Seattle, Portland, Denver, and Salt Lake City support advanced neuroscience and research programs. Their health systems often evaluate AI-enabled devices through system-wide clinical governance, making interoperability and measurable operational benefit especially important. Remote monitoring and tele-neurology are also relevant because large geographic catchment areas extend beyond major metropolitan centers.

Arizona and Nevada are high-growth state markets because of population expansion and a rising share of older residents. Demand is increasing for stroke triage, dementia assessment, movement-disorder management, and connected neurological monitoring. Phoenix, Tucson, Las Vegas, and Reno are expanding specialist capacity, but many surrounding communities continue to face uneven neurological access. AI-enabled devices that support hub-and-spoke stroke networks, rapid EEG, and remote follow-up can address this gap. New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii represent smaller but strategically important markets for tele-neurology and portable monitoring because distance and workforce constraints increase the value of scalable technology.

The West is expected to maintain the highest adoption intensity through 2035. Growth will be driven by hospital digital transformation, software-device convergence, clinical trials using digital biomarkers, expansion of AI-enabled imaging, and investment in robotics and precision neurosurgery. Vendors entering the region must be prepared for sophisticated technical evaluation and strong competition, but successful deployments can serve as high-visibility reference sites for national expansion.

South

The South represented an estimated USD 0.78 billion in 2025 and is projected to reach approximately USD 4.38 billion by 2035, expanding at a CAGR of about 18.83%. The region includes Delaware, Maryland, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida, Kentucky, Tennessee, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, and Texas, together with the District of Columbia. The South has the largest population base among the four regions and contains many states with elevated stroke, hypertension, diabetes, obesity, and dementia burden.

Texas and Florida are the two largest state opportunities in the South. Texas has major neuroscience and trauma hubs in Houston, Dallas-Fort Worth, Austin, and San Antonio, along with large rural catchment areas that support hub-and-spoke stroke and tele-neurology models. Florida’s older population creates substantial demand for stroke care, Alzheimer’s assessment, Parkinson’s management, neuromodulation, and rehabilitation. Both states contain large health systems capable of enterprise purchasing and community hospitals that need scalable access to specialist support. Vendors that can serve both high-acuity centers and distributed networks are well positioned.

North Carolina, Georgia, Tennessee, Virginia, and Maryland are important adoption markets because they combine population growth, academic research, and expanding health-system infrastructure. Research Triangle institutions, Atlanta-based provider networks, Nashville healthcare organizations, Northern Virginia systems, and the Baltimore-Washington corridor provide strong environments for clinical validation and commercialization. These states are likely to adopt AI-enabled neurosurgery, stroke coordination, EEG analytics, and remote monitoring at above-average rates, particularly when solutions support service-line growth and referral capture.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, West Virginia, and Oklahoma face some of the country’s most persistent neurological access and vascular-risk challenges. Large portions of these states are rural, and specialist shortages can delay stroke evaluation, EEG interpretation, and follow-up for chronic neurological conditions. The commercial opportunity is therefore different from that in major academic centers. Portable, easy-to-deploy, cloud-connected devices and network-level workflow platforms may create greater value than premium stand-alone capital systems. Reimbursement support and implementation services are essential because smaller hospitals have limited digital transformation budgets.

The South is expected to deliver the greatest absolute revenue increase through 2035. Expansion will be supported by population growth, aging, stroke-network modernization, rising neuroscience capital investment, and adoption of remote monitoring across large geographic service areas. Competition will intensify as national health systems standardize vendors across multi-state footprints. Companies that demonstrate reductions in transfer delays, length of stay, unnecessary intensive-care utilization, and specialist workload will have the strongest procurement position.

Northeast

The Northeast accounted for an estimated USD 0.69 billion in 2025 and is projected to reach approximately USD 3.60 billion by 2035, reflecting a CAGR of about 17.96%. The region includes Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, and Pennsylvania. It remains one of the highest-value regions on a per-patient and per-procedure basis because of its concentration of academic medical centers, neuroscience institutes, research hospitals, specialist physicians, and complex referral care.

New York is the largest state market in the Northeast. New York City and major upstate systems support high volumes of stroke, epilepsy, neurosurgery, neurocritical care, dementia, and movement-disorder cases. The state’s large hospital networks are attractive for enterprise AI deployment, but purchasing decisions require evidence across diverse patient populations and multiple facility types. New Jersey benefits from proximity to New York and Philadelphia, a strong life-sciences base, and dense private-provider networks. Both states are important for scaling imaging, EEG, and connected neurology platforms.

Massachusetts is one of the most influential states despite its smaller population. Boston’s academic medical centers, research institutions, digital health companies, and venture ecosystem make the state a leading site for clinical trials, algorithm development, and early adoption. Connecticut and Rhode Island benefit from regional referral networks and close links to major academic systems. Pennsylvania provides a large and diverse market through Philadelphia, Pittsburgh, and statewide community networks, supporting both advanced neuroscience technology and rural-access solutions.

Maine, New Hampshire, and Vermont are smaller markets but illustrate the need for distributed neurological care. Their rural populations and long travel distances increase the value of tele-neurology, cloud imaging, portable EEG, and home monitoring. Health systems in these states are likely to prioritize technologies that reduce unnecessary transfers and allow specialists to supervise care across multiple facilities. Vendors must offer efficient deployment and support because individual site volumes may be lower than in large urban centers.

The Northeast will grow slightly below the national average because many leading institutions already use advanced digital and imaging tools. However, it will remain disproportionately important for evidence generation, complex neurosurgery, adaptive stimulation, and clinical adoption of next-generation devices. Procurement committees in the region tend to demand rigorous clinical performance, transparent model governance, and strong health-economic documentation. Success in the Northeast can strengthen national credibility, but competitive barriers are high.

Midwest

The Midwest represented an estimated USD 0.47 billion in 2025 and is projected to reach approximately USD 2.29 billion by 2035, corresponding to a CAGR of about 17.16%. The region includes Ohio, Indiana, Illinois, Michigan, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota. Demand is supported by established neuroscience programs, large integrated delivery networks, major community hospital systems, and significant chronic neurological and vascular disease burden.

Illinois, Ohio, Michigan, and Minnesota are the largest state markets in the region. Chicago supports a broad academic and community hospital ecosystem with demand for stroke AI, neuroimaging, epilepsy monitoring, and neurosurgery. Ohio has nationally prominent cardiovascular and neurological centers and a large multi-city provider base. Michigan combines major academic programs with substantial community-hospital demand. Minnesota is especially important because of its medtech industry, clinical research infrastructure, and expertise in neuromodulation, imaging, and connected devices.

Wisconsin, Indiana, Missouri, Iowa, and Kansas provide stable opportunities for enterprise health-system adoption. These states have strong regional referral networks and many hospitals serving mixed urban and rural populations. AI-enabled stroke coordination, rapid EEG, remote movement monitoring, and surgical navigation can help standardize care across system footprints. Buyers in these markets are often highly focused on service reliability, integration, and total cost of ownership. Vendors with strong clinical support teams and flexible contracting can perform well.

Nebraska, North Dakota, and South Dakota are smaller markets but have clear need for portable and remote neurological technologies. Long travel distances and limited specialist density create demand for cloud-based imaging review, tele-stroke workflows, wearable monitoring, and digital rehabilitation. The revenue potential per site is lower than in major metropolitan centers, but regional networks can create meaningful scale when platforms are contracted across multiple facilities. Partnerships with integrated systems and statewide care initiatives can accelerate adoption.

The Midwest is expected to remain a durable market rather than the fastest-growing region. Manufacturers will succeed by demonstrating operational value, providing dependable implementation, and supporting clinical education. The region is likely to be particularly important for adaptive neuromodulation, stroke-network standardization, portable EEG, and enterprise contracts that span academic hubs and community hospitals. Its established medtech base also supports device development and manufacturing partnerships.

Key Market Players

The U.S. AI-Enabled Neurology Devices Competitive Landscape is fragmented but becoming increasingly platform oriented. Large medtech companies control important positions in neuromodulation, surgical navigation, imaging, and neurointervention, while specialized digital health companies lead in stroke coordination, EEG analytics, seizure monitoring, cognitive assessment, and digital biomarkers. Competition is shaped by FDA authorization, access to proprietary clinical data, integration with hospital systems, evidence quality, installed-base leverage, and the ability to support nationwide deployment.

Leading companies increasingly compete on workflow ownership rather than on a single algorithm. Imaging and stroke vendors seek to manage communication across the emergency department, radiology, neurology, and transfer center. EEG companies combine acquisition hardware, disposable sensors, automated analysis, and remote review. Neuromodulation manufacturers integrate implants, sensing, programming, and patient monitoring. Navigation companies combine imaging, registration, planning, robotics, and instruments. This platform shift favors companies that can create recurring revenue and embed their technology into clinical operations.

Some of the key players in the U.S. AI-Enabled Neurology Devices industry are

Medtronic,
Abbott Laboratories,
Boston Scientific Corporation,
Stryker Corporation,
Penumbra, Inc.,
GE HealthCare,
Siemens Healthineers,
Philips Healthcare,
Canon Medical Systems USA,
Brainlab,
Viz.ai,
RapidAI,
Aidoc,
Avicenna.AI,
Brainomix,
Ceribell, Inc.,
Empatica,
BrainScope Company, Inc.,
Oculogica, Inc.,
NeuroPace, Inc.,
Neuronetics, Inc.,
LivaNova PLC,
ClearPoint Neuro, Inc.,
Rune Labs,
Neuro Event Labs.

Medtronic, Abbott, Boston Scientific, and NeuroPace are strategically important in neuromodulation and implantable therapy. Stryker and Penumbra hold strong positions in neurovascular intervention and can use procedural portfolios to integrate AI-enabled workflow and navigation. GE HealthCare, Siemens Healthineers, Philips, and Canon Medical influence the market through imaging systems, reconstruction, workflow software, and enterprise hospital relationships. Brainlab and ClearPoint Neuro are relevant in neurosurgical planning, navigation, and image-guided intervention.

Viz.ai, RapidAI, Aidoc, Avicenna.AI, and Brainomix are prominent in AI-enabled imaging and acute neurological workflow. Ceribell has built a differentiated position in rapid EEG and neurocritical care monitoring. Empatica and Neuro Event Labs address wearable or video-based seizure detection. BrainScope and Oculogica focus on neurological assessment, including brain injury. Rune Labs develops data and digital biomarker capabilities for neurodegenerative and movement disorders. Market share through 2035 will be influenced by prospective clinical evidence, alert accuracy, interoperability, reimbursement strategy, service quality, cybersecurity, and the ability to prove economic value across health-system networks.

Recent Developments

Recent developments in the U.S. AI-Enabled Neurology Devices Market show a clear shift from imaging-only applications toward sensing, prediction, monitoring, and adaptive therapy. The FDA’s AI-enabled medical device list now includes more than 1,500 authorized devices across specialties. Although radiology remains dominant, the neurology panel includes a growing range of EEG, seizure, cognitive assessment, tremor, navigation, and monitoring devices. This indicates that AI is becoming embedded in active neurological care rather than remaining a back-end image-analysis function.

In January 2024, the FDA granted De Novo authorization to BrainSee, a software device intended to support assessment of the likelihood that certain patients with amnestic mild cognitive impairment will progress to clinical Alzheimer’s disease dementia within five years. The authorization was strategically important because it established a regulated category for AI-enabled prognostic assessment in cognitive disease. It also highlighted the increasing role of quantitative imaging and predictive models in identifying patients who may require closer monitoring or specialist evaluation.

During 2024, the neurology device pipeline expanded in EEG and monitoring. FDA-authorized products included machine-learning EEG scoring and seizure-detection modules, wearable seizure monitoring, sleep-stage analytics, and automated registration for navigation. These authorizations demonstrated growing regulatory acceptance of devices that interpret physiologic signals and support real-time clinical workflows. They also increased competition among portable EEG, cloud analysis, and home-monitoring companies.

In June 2025, Empatica received FDA clearance for an updated EpiMonitor system using a wearable device and mobile application to support seizure monitoring in adults and children aged six years and older. The system uses motion and electrodermal activity signals to identify patterns associated with generalized tonic-clonic seizures and can alert designated caregivers. This development illustrates the movement of neurological monitoring into home and everyday environments, where continuous data can complement episodic clinic assessment.

In July 2025, the FDA cleared the Felix NeuroAI System, a wrist-worn external stimulator for adults with essential tremor. The device uses an accelerometer and closed-loop logic to determine whether stimulation should be activated and at what intensity. The clearance is important because it demonstrates how AI-enabled sensing and adaptive stimulation can be combined in a non-implantable therapeutic device. It also increases competitive pressure in tremor management, where patients and clinicians are seeking alternatives to medication and invasive procedures.

In December 2025, the FDA cleared the Ceribell Delirium Monitor System for use as an aid in screening and monitoring delirium in adult critical-care patients. The system analyzes EEG features with a machine-learning model and provides repeated assessments during monitoring. The product expands Ceribell’s commercial opportunity beyond seizure detection and reflects a broader trend toward using accessible EEG as a general neurological vital sign in intensive care. Hospitals will evaluate such devices based on clinical validation, nursing workflow, false-alarm burden, and impact on specialist utilization.

In March 2026, the FDA cleared Medtronic’s Stealth AXiS Cranial clinical application for use with its surgical navigation system in cranial procedures such as tumor resection, ventricular catheter placement, biopsies, and depth-electrode or probe placement. The development reflects continued investment by large medtech companies in software-driven neurosurgery and integrated navigation. Over the next several years, similar platforms are expected to incorporate more automated segmentation, trajectory planning, intraoperative decision support, and connection to robotic systems.

The competitive landscape is also being reshaped by partnerships between device companies, cloud platforms, imaging vendors, and health systems. Large manufacturers are likely to acquire or partner with specialized AI companies to accelerate entry into stroke workflow, digital biomarkers, and remote neurological monitoring. Smaller firms will continue to create clinically focused products, but scaling will require regulatory resources, enterprise sales capability, cybersecurity infrastructure, and evidence across diverse clinical sites. Consolidation is therefore expected as the market moves from point solutions toward broader neurological care platforms.

Conclusion

The U.S. AI-Enabled Neurology Devices Market Size & Share is positioned for rapid expansion from USD 2.76 billion in 2025 to approximately USD 15.08 billion by 2035, supported by an 18.51% CAGR during the forecast period. The market’s long-term strength is grounded in the high burden of stroke, epilepsy, dementia, Parkinson’s disease, brain injury, and other neurological conditions; the limited availability of specialist expertise; and the growing need to interpret complex imaging and biosignal data at scale.

The most attractive opportunities will emerge in AI-enabled stroke networks, rapid and continuous EEG, wearable seizure monitoring, adaptive neuromodulation, predictive cognitive assessment, digital biomarkers, neurosurgical navigation, and connected rehabilitation. Neuroimaging will remain the largest product category, but value growth will increasingly shift toward devices that sense continuously, personalize therapy, or coordinate care across multiple settings. Products that combine hardware, software, disposables, and recurring data services will create more durable revenue models than isolated algorithms.

Regional opportunity will be led by the West’s innovation and digital adoption, followed closely by the South’s population scale and neurological disease burden. The Northeast will remain essential for high-acuity care, evidence generation, and early adoption of advanced devices. The Midwest will provide stable growth through integrated delivery networks, medtech expertise, and demand for scalable solutions across urban and rural systems. California, Texas, Florida, New York, Massachusetts, Pennsylvania, Illinois, Ohio, Minnesota, North Carolina, Georgia, Arizona, Washington, and Michigan will remain especially important state markets.

For clients evaluating this market, the central question is not whether AI will become part of neurological devices. The more important questions are which applications will achieve measurable clinical impact, which vendors can integrate into real-world workflows, and how procurement will shift as health systems reduce the number of digital suppliers. Companies that combine regulated device performance, specialist trust, workflow efficiency, model governance, reimbursement support, and real-world economic evidence will define the next decade of the U.S. AI-enabled neurology devices industry.

TABLE OF CONTENT

1. U.S. AI-Enabled Neurology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Clinical and Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Analytical Frameworks & Forecasting Models
1.3.6. Data Triangulation, Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. AI-Enabled Neurology Device Manufacturers
1.6.2. Neuroimaging, EEG and Biosignal Technology Suppliers
1.6.3. AI Algorithm, Cloud and Data Infrastructure Providers
1.6.4. Hospitals and Integrated Delivery Networks
1.6.5. Comprehensive Stroke Centers and Neuroscience Institutes
1.6.6. Neurology Practices, Epilepsy Centers and Diagnostic Clinics
1.6.7. Rehabilitation, Home Monitoring and Caregiver Networks
1.6.8. Group Purchasing Organizations, Distributors and Technology Integrators
1.6.9. Payers, Regulators and Clinical Decision-Makers

What this section provides: This section defines the market boundary, study scope, research methodology, assumptions and stakeholder ecosystem so clients understand how the U.S. AI-enabled neurology devices market is measured, segmented and validated.

2. U.S. AI-Enabled Neurology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Product and Application Areas
2.8. Leading Regional and State-Level Opportunity Markets
2.9. Strategic Implications for Manufacturers and Investors

What this section provides: This section gives decision-makers a concise view of market size, growth trajectory, adoption drivers, competitive intensity, regional performance and priority investment opportunities.

3. U.S. AI-Enabled Neurology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Burden of Stroke, Epilepsy and Neurodegenerative Disorders
3.1.2. Shortage of Neurologists and Neurophysiology Specialists
3.1.3. Time-Critical Demand for AI-Assisted Stroke Detection and Triage
3.1.4. Expansion of Rapid EEG and Continuous Seizure Monitoring
3.1.5. Growth of Adaptive and Closed-Loop Neuromodulation
3.1.6. Increasing Adoption of Digital Neurological Biomarkers
3.1.7. Hospital Investment in Neuroscience Service-Line Modernization
3.1.8. Expansion of Home-Based Neurological Monitoring
3.2. Restraints and Their Impact Analysis
3.2.1. High Device Development, Validation and Implementation Costs
3.2.2. Reimbursement Uncertainty for AI-Based Neurological Workflows
3.2.3. Limited Prospective and Real-World Clinical Evidence
3.2.4. Interoperability Barriers Across Imaging, EEG and EHR Systems
3.2.5. Cybersecurity, Privacy and Protected Health Information Risks
3.2.6. Algorithm Bias, False Alerts and Generalizability Concerns
3.2.7. Clinician Trust and Resistance to Workflow Change
3.3. Opportunities and Their Impact Analysis
3.3.1. Enterprise AI-Enabled Stroke Networks
3.3.2. Rapid EEG Deployment in Emergency and Critical Care
3.3.3. Wearable Seizure and Movement-Disorder Monitoring
3.3.4. Adaptive Deep Brain and Responsive Neurostimulation
3.3.5. Predictive Cognitive Assessment and Dementia-Risk Stratification
3.3.6. AI-Assisted Neurosurgical Navigation and Robotic Intervention
3.3.7. Digital Biomarkers for Clinical Trials and Therapy Monitoring
3.3.8. Rural Teleneurology and Distributed Neurological Care
3.4. Challenges and Their Impact Analysis
3.4.1. Diverse and Fragmented Neurological Data Sources
3.4.2. Model Drift and Post-Market Algorithm Monitoring
3.4.3. Clinical Liability and Human Oversight Requirements
3.4.4. Lengthy Hospital Procurement and Cybersecurity Review Cycles
3.4.5. Scaling Point Solutions Across Multi-Hospital Networks
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Hospital Capital Procurement Behavior Analysis
3.8. AI Device Adoption Readiness Analysis
3.9. Reimbursement and Return-on-Investment Impact Analysis

What this section provides: This section explains the clinical, commercial, reimbursement, regulatory and operational forces shaping demand, helping clients evaluate market upside, adoption barriers and execution risks.

4. U.S. AI-Enabled Neurology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. AI Algorithm and Neurological Data Value Chain
4.6. Cloud, Edge and Connected Neurology Infrastructure Analysis
4.7. Application & Innovation Landscape
4.8. FDA Regulatory Framework for AI-Enabled Medical Devices
4.8.1. Software as a Medical Device Regulatory Pathways
4.8.2. 510(k), De Novo and Premarket Approval Considerations
4.8.3. Predetermined Change Control Plans
4.8.4. Good Machine Learning Practice Requirements
4.8.5. Post-Market Performance and Algorithm Update Oversight
4.9. CMS Reimbursement and Coverage Landscape
4.10. HIPAA, Cybersecurity and Neurological Data Privacy Analysis
4.11. Algorithmic Bias, Health Equity and Patient Diversity Analysis
4.12. Import, Export and Tariff Impact
4.13. Government Neuroscience and Public Health Initiatives
4.14. Impact of Escalating Geopolitical and Technology-Supply Tensions
4.15. Hospital Value Analysis Committee Decision Framework
4.16. Enterprise AI Governance and Vendor Approval Framework

What this section provides: This section gives clients a complete view of the external market environment, including regulation, reimbursement, pricing, data governance, cybersecurity, clinical evidence, supply chains and hospital procurement requirements.

5. U.S. AI-Enabled Neurology Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. AI-Enabled Neuroimaging and Stroke-Triage Systems
5.1.2.1. Large-Vessel Occlusion Detection Systems
5.1.2.2. Intracranial Hemorrhage Detection Systems
5.1.2.3. CT and MRI Perfusion Analysis Platforms
5.1.2.4. Quantitative Brain Imaging and Volumetry Systems
5.1.2.5. AI-Enabled Stroke Workflow and Communication Platforms
5.1.3. AI-Enabled EEG and Seizure-Monitoring Devices
5.1.3.1. Rapid-Application EEG Systems
5.1.3.2. Continuous EEG Monitoring Systems
5.1.3.3. Automated Seizure Detection and Burden Analysis
5.1.3.4. Wearable Seizure Detection Devices
5.1.3.5. Cloud-Based EEG Interpretation Platforms
5.1.4. Intelligent Neuromodulation and Implantable Neurological Devices
5.1.4.1. Adaptive Deep Brain Stimulation Systems
5.1.4.2. Responsive Neurostimulation Systems
5.1.4.3. AI-Assisted Vagus Nerve Stimulation Systems
5.1.4.4. Closed-Loop Tremor Stimulation Devices
5.1.4.5. Sensing-Enabled Implantable Pulse Generators
5.1.5. AI-Assisted Surgical Navigation and Neurointerventional Systems
5.1.5.1. Cranial Surgical Navigation Systems
5.1.5.2. Robotic Neurosurgical Planning Systems
5.1.5.3. Automated Image Registration and Segmentation Systems
5.1.5.4. Neurovascular Procedure Planning Platforms
5.1.5.5. AI-Enabled Thrombectomy Workflow Systems
5.1.6. Wearable, Digital Biomarker and Neurorehabilitation Devices
5.1.6.1. Movement and Gait Monitoring Devices
5.1.6.2. Digital Cognitive Assessment Devices
5.1.6.3. Speech, Voice and Motor Analysis Devices
5.1.6.4. Eye-Tracking and Oculomotor Assessment Systems
5.1.6.5. Robotic and Sensor-Enabled Rehabilitation Devices
5.1.6.6. Brain-Computer Interface Devices

What this section provides: This section identifies the AI-enabled neurology device categories expected to generate the highest revenue contribution, strongest recurring revenue and fastest growth through 2035.

6. U.S. AI-Enabled Neurology Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Stroke and Cerebrovascular Disease Management
6.1.2.1. Acute Ischemic Stroke Detection
6.1.2.2. Hemorrhagic Stroke Detection
6.1.2.3. Stroke Triage and Transfer Coordination
6.1.2.4. Neurointerventional Procedure Planning
6.1.2.5. Post-Stroke Monitoring and Rehabilitation
6.1.3. Epilepsy and Seizure Management
6.1.3.1. Inpatient and Critical-Care Seizure Monitoring
6.1.3.2. Ambulatory EEG Monitoring
6.1.3.3. Home-Based Seizure Detection
6.1.3.4. Caregiver Alert and Safety Systems
6.1.3.5. Responsive and Closed-Loop Epilepsy Therapy
6.1.4. Neurodegenerative Disease Management
6.1.4.1. Alzheimer’s Disease and Cognitive Decline
6.1.4.2. Parkinson’s Disease
6.1.4.3. Multiple Sclerosis
6.1.4.4. Amyotrophic Lateral Sclerosis
6.1.4.5. Disease Progression and Therapy-Response Monitoring
6.1.5. Movement Disorders and Tremor Management
6.1.5.1. Essential Tremor
6.1.5.2. Parkinsonian Motor Symptoms
6.1.5.3. Dystonia
6.1.5.4. Gait and Balance Disorders
6.1.5.5. Adaptive Stimulation and Digital Motor Assessment
6.1.6. Neurosurgery, Brain Injury, Neurocritical Care and Rehabilitation
6.1.6.1. Brain Tumor and Lesion Planning
6.1.6.2. Traumatic Brain Injury Assessment
6.1.6.3. Delirium and Neurocritical Care Monitoring
6.1.6.4. Hydrocephalus and Intracranial Procedure Guidance
6.1.6.5. Postoperative Neurological Surveillance
6.1.6.6. Motor and Cognitive Rehabilitation

What this section provides: This section helps clients understand demand by neurological use case and prioritize applications with strong clinical urgency, device utilization, reimbursement potential and workflow value.

7. U.S. AI-Enabled Neurology Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Hospitals and Integrated Health Systems
7.1.2.1. Tertiary and Quaternary Hospitals
7.1.2.2. Community Hospitals
7.1.2.3. Emergency and Trauma Centers
7.1.2.4. Intensive and Neurocritical Care Units
7.1.3. Comprehensive Stroke Centers, Neuroscience Institutes and Academic Medical Centers
7.1.3.1. Comprehensive Stroke Centers
7.1.3.2. Neuroscience Institutes
7.1.3.3. Academic Medical Centers
7.1.3.4. Clinical Research and Trial Centers
7.1.4. Neurology Practices, Epilepsy Centers, Sleep Laboratories and Diagnostic Clinics
7.1.4.1. Independent Neurology Practices
7.1.4.2. Epilepsy Monitoring Centers
7.1.4.3. Sleep and Neurophysiology Laboratories
7.1.4.4. Diagnostic Imaging and Cognitive Assessment Centers
7.1.5. Ambulatory Surgery Centers and Specialized Neurosurgical Facilities
7.1.5.1. Neurosurgical Ambulatory Centers
7.1.5.2. Neuromodulation and Pain Intervention Centers
7.1.5.3. Outpatient Neurodiagnostic Facilities
7.1.6. Home Healthcare, Rehabilitation and Remote Monitoring Providers
7.1.6.1. Home Neurological Monitoring Programs
7.1.6.2. Inpatient and Outpatient Rehabilitation Centers
7.1.6.3. Caregiver-Supported Monitoring Networks
7.1.6.4. Virtual Neurology and Teleneurology Providers

What this section provides: This section explains which care settings and customer groups are expected to drive capital purchasing, enterprise software adoption, recurring monitoring demand and AI-enabled neurological workflow deployment.

8. U.S. AI-Enabled Neurology Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Machine Learning and Deep Learning
8.1.2.1. Supervised Learning
8.1.2.2. Unsupervised and Self-Supervised Learning
8.1.2.3. Convolutional Neural Networks
8.1.2.4. Transformer-Based Models
8.1.3. Computer Vision and Advanced Image Processing
8.1.3.1. Image Classification and Abnormality Detection
8.1.3.2. Anatomical Segmentation
8.1.3.3. Image Reconstruction and Enhancement
8.1.3.4. Surgical Registration and Navigation
8.1.4. Predictive Analytics and Multimodal Biosignal Processing
8.1.4.1. EEG and Electrophysiological Signal Analytics
8.1.4.2. Movement, Gait and Accelerometry Analytics
8.1.4.3. Speech, Voice and Cognitive Analytics
8.1.4.4. Multimodal Risk Prediction
8.1.5. Closed-Loop and Adaptive Intelligence
8.1.5.1. Responsive Neurostimulation
8.1.5.2. Adaptive Deep Brain Stimulation
8.1.5.3. Closed-Loop Wearable Stimulation
8.1.5.4. Real-Time Rehabilitation Feedback
8.1.6. Cloud, Edge and Hybrid AI Architectures
8.1.6.1. Cloud-Based AI Platforms
8.1.6.2. Edge and On-Device Intelligence
8.1.6.3. Hybrid Cloud-Edge Systems
8.1.6.4. Embedded AI in Imaging and Neurological Devices

What this section provides: This section evaluates the AI, imaging, biosignal, adaptive-control and deployment technologies shaping neurological diagnosis, monitoring, intervention and rehabilitation.

9. U.S. AI-Enabled Neurology Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Direct Hospital and Health-System Procurement
9.1.3. Integrated Delivery Network Enterprise Contracts
9.1.4. Group Purchasing Organization and Aggregated Contracts
9.1.5. Distributor and Specialty Technology Integrator Sales
9.1.6. Direct Procurement by Neurology Practices and Diagnostic Centers
9.1.7. Subscription, Per-Use and Managed-Service Procurement
9.1.8. Capital Leasing and Equipment-as-a-Service Models
9.1.9. Research Institution and Life-Science Partnership Contracts

What this section provides: This section helps clients understand how AI-enabled neurology devices are purchased in the U.S., including enterprise contracting, GPO influence, subscription models, capital leasing and specialist-practice procurement.

10. U.S. AI-Enabled Neurology Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Neurological Disease Burden Analysis
10.1.4. Regional Stroke Center, Neuroscience and Neuroimaging Infrastructure Analysis
10.1.5. Regional AI Adoption and Digital Health Readiness Analysis
10.1.6. Regional Reimbursement and Procurement Dynamics

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region AI-Enabled Neurology Device Manufacturers, Innovation Hubs and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region AI-Enabled Neurology Device Manufacturers, Academic Innovation Hubs and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region AI-Enabled Neurology Device Manufacturers, Clinical Networks and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region AI-Enabled Neurology Device Manufacturers, Medtech Hubs and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level analysis, helping clients identify priority U.S. geographies, stroke and neuroscience infrastructure, AI-adoption hotspots, underserved markets and state-level commercial opportunities.

11. U.S. AI-Enabled Neurology Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking Analysis
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Product Portfolio and Application Coverage Matrix
11.5. Clinical Evidence and FDA Authorization Benchmarking
11.6. Partnership, Acquisition and Collaboration Analysis
11.7. Company Profiles
11.7.1. Medtronic
11.7.2. Abbott Laboratories
11.7.3. Boston Scientific Corporation
11.7.4. Stryker Corporation
11.7.5. Penumbra, Inc.
11.7.6. GE HealthCare
11.7.7. Siemens Healthineers
11.7.8. Philips Healthcare
11.7.9. Canon Medical Systems USA
11.7.10. Brainlab
11.7.11. Viz.ai
11.7.12. RapidAI
11.7.13. Aidoc
11.7.14. Avicenna.AI
11.7.15. Brainomix
11.7.16. Ceribell, Inc.
11.7.17. Empatica
11.7.18. BrainScope Company, Inc.
11.7.19. Oculogica, Inc.
11.7.20. NeuroPace, Inc.
11.7.21. Neuronetics, Inc.
11.7.22. LivaNova PLC
11.7.23. ClearPoint Neuro, Inc.
11.7.24. Rune Labs
11.7.25. Neuro Event Labs

Note: Each company profile will include company overview, AI-enabled neurology device portfolio, U.S. market strategy, financial positioning, clinical evidence, regulatory status, technology partnerships, commercialization model and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, clinical and regulatory intelligence, partnership activity and strategic insight into major AI-enabled neurology device companies.

12. U.S. AI-Enabled Neurology Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Multimodal Neurological AI and Foundation Models
12.2.2. Adaptive and Closed-Loop Neuromodulation
12.2.3. AI-Enabled Stroke Network Orchestration
12.2.4. Continuous EEG and Neurological Vital-Sign Monitoring
12.2.5. Predictive Cognitive Assessment and Digital Biomarkers
12.2.6. Brain-Computer Interfaces and Neural Signal Decoding
12.2.7. AI-Assisted Neurosurgical Robotics
12.2.8. Federated Learning, Synthetic Data and Privacy-Preserving AI
12.3. Emerging Business Trends
12.3.1. Shift from Point Solutions to Enterprise Neurology Platforms
12.3.2. Hardware, Software and Data-Service Bundling
12.3.3. Growth of Outcome-Based Commercial Agreements
12.3.4. Expansion of Home and Remote Neurological Monitoring
12.3.5. Partnerships Between Medtech and AI Software Companies
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Product and Application Opportunity Heatmap
12.7. Technology Adoption Timeline, 2026–2035

What this section provides: This section prepares clients for future technology shifts, market-structure changes, investment opportunities and potential adoption scenarios through 2035.

13. U.S. AI-Enabled Neurology Devices Market: Strategic Recommendations

13.1. Recommendations for Neurology Device Manufacturers
13.2. Recommendations for AI and Clinical Software Developers
13.3. Recommendations for Hospitals and Integrated Health Systems
13.4. Recommendations for Stroke Centers and Neuroscience Institutes
13.5. Recommendations for Investors and Private Equity Firms
13.6. Recommendations for Distributors and Technology Integrators
13.7. Recommendations for New Entrants and Startups
13.8. Go-to-Market Strategy Considerations
13.9. Product Positioning and Portfolio Expansion Guidance
13.10. Clinical Evidence and Regulatory Strategy Guidance
13.11. Reimbursement and Health-Economic Evidence Strategy
13.12. Enterprise Integration and Cybersecurity Strategy
13.13. Partnership, Licensing and Acquisition Strategy

What this section provides: This section converts market intelligence into actionable strategies for product development, evidence generation, regulatory planning, commercialization, channel expansion, investment and competitive differentiation.

14. U.S. AI-Enabled Neurology Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Market Sizing and Forecasting Limitation
14.4. AI Technology and Regulatory Change Limitation
14.5. Legal Disclaimer
14.6. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s scope limitations, legal boundaries, data-use terms, forecasting assumptions and risks associated with evolving AI technologies and regulatory frameworks.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. AI-Enabled Neurology Devices Market: Market Definition and Scope
TABLE 3: U.S. AI-Enabled Neurology Devices Market: Research Methodology Framework
TABLE 4: U.S. AI-Enabled Neurology Devices Market: Key Assumptions
TABLE 5: U.S. AI-Enabled Neurology Devices Market: Market Ecosystem Overview
TABLE 6: U.S. AI-Enabled Neurology Devices Market: Stakeholder Analysis
TABLE 7: U.S. AI-Enabled Neurology Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. AI-Enabled Neurology Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. AI-Enabled Neurology Devices Market: Market Attractiveness Index
TABLE 10: U.S. AI-Enabled Neurology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. AI-Enabled Neurology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. AI-Enabled Neurology Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. AI-Enabled Neurology Devices Market: Drivers; Impact Analysis
TABLE 14: U.S. AI-Enabled Neurology Devices Market: Restraints; Impact Analysis
TABLE 15: U.S. AI-Enabled Neurology Devices Market: Opportunities; Impact Analysis
TABLE 16: U.S. AI-Enabled Neurology Devices Market: Challenges; Impact Analysis
TABLE 17: U.S. AI-Enabled Neurology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 18: U.S. AI-Enabled Neurology Devices Market: Clinical Workflow Economics Matrix
TABLE 19: U.S. AI-Enabled Neurology Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 20: U.S. AI-Enabled Neurology Devices Market: AI Device Adoption Readiness Analysis
TABLE 21: U.S. AI-Enabled Neurology Devices Market: Reimbursement and Return-on-Investment Analysis
TABLE 22: U.S. AI-Enabled Neurology Devices Market: PESTEL Analysis
TABLE 23: U.S. AI-Enabled Neurology Devices Market: Porter’s Five Forces Analysis
TABLE 24: U.S. AI-Enabled Neurology Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 25: U.S. AI-Enabled Neurology Devices Market: Value Chain Analysis
TABLE 26: U.S. AI-Enabled Neurology Devices Market: Supply Chain Analysis
TABLE 27: U.S. AI-Enabled Neurology Devices Market: AI Algorithm and Neurological Data Value Chain
TABLE 28: U.S. AI-Enabled Neurology Devices Market: Cloud, Edge and Connected Neurology Infrastructure
TABLE 29: U.S. AI-Enabled Neurology Devices Market: Application & Innovation Landscape
TABLE 30: U.S. AI-Enabled Neurology Devices Market: FDA Regulatory Framework Analysis
TABLE 31: U.S. AI-Enabled Neurology Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 32: U.S. AI-Enabled Neurology Devices Market: HIPAA, Cybersecurity and Neurological Data Privacy Analysis
TABLE 33: U.S. AI-Enabled Neurology Devices Market: Algorithmic Bias, Health Equity and Patient Diversity Analysis
TABLE 34: U.S. AI-Enabled Neurology Devices Market: Import, Export and Tariff Impact
TABLE 35: U.S. AI-Enabled Neurology Devices Market: Government Neuroscience and Public Health Initiatives
TABLE 36: U.S. AI-Enabled Neurology Devices Market: Impact of Geopolitical and Technology-Supply Tensions
TABLE 37: U.S. AI-Enabled Neurology Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 38: U.S. AI-Enabled Neurology Devices Market: Enterprise AI Governance and Vendor Approval Framework
TABLE 39: U.S. AI-Enabled Neurology Devices Market: Product Type Snapshot, 2025
TABLE 40: Segment Dashboard; Definition and Scope, by Product Type
TABLE 41: U.S. AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 42: U.S. AI-Enabled Neurology Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 43: U.S. AI-Enabled Neurology Devices Market: AI-Enabled Neuroimaging and Stroke-Triage Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. AI-Enabled Neurology Devices Market: AI-Enabled EEG and Seizure-Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. AI-Enabled Neurology Devices Market: Intelligent Neuromodulation and Implantable Neurological Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. AI-Enabled Neurology Devices Market: AI-Assisted Surgical Navigation and Neurointerventional Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. AI-Enabled Neurology Devices Market: Wearable, Digital Biomarker and Neurorehabilitation Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. AI-Enabled Neurology Devices Market: Application Snapshot, 2025
TABLE 49: Segment Dashboard; Definition and Scope, by Application
TABLE 50: U.S. AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 51: U.S. AI-Enabled Neurology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 52: U.S. AI-Enabled Neurology Devices Market: Stroke and Cerebrovascular Disease Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. AI-Enabled Neurology Devices Market: Epilepsy and Seizure Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. AI-Enabled Neurology Devices Market: Neurodegenerative Disease Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. AI-Enabled Neurology Devices Market: Movement Disorders and Tremor Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. AI-Enabled Neurology Devices Market: Neurosurgery, Brain Injury, Neurocritical Care and Rehabilitation Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. AI-Enabled Neurology Devices Market: End User Snapshot, 2025
TABLE 58: Segment Dashboard; Definition and Scope, by End User
TABLE 59: U.S. AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 60: U.S. AI-Enabled Neurology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 61: U.S. AI-Enabled Neurology Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. AI-Enabled Neurology Devices Market: Comprehensive Stroke Centers, Neuroscience Institutes and Academic Medical Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. AI-Enabled Neurology Devices Market: Neurology Practices, Epilepsy Centers, Sleep Laboratories and Diagnostic Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. AI-Enabled Neurology Devices Market: Ambulatory Surgery Centers and Specialized Neurosurgical Facilities Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. AI-Enabled Neurology Devices Market: Home Healthcare, Rehabilitation and Remote Monitoring Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. AI-Enabled Neurology Devices Market: Technology Type Snapshot, 2025
TABLE 67: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 68: U.S. AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 69: U.S. AI-Enabled Neurology Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 70: U.S. AI-Enabled Neurology Devices Market: Machine Learning and Deep Learning Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. AI-Enabled Neurology Devices Market: Computer Vision and Advanced Image Processing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. AI-Enabled Neurology Devices Market: Predictive Analytics and Multimodal Biosignal Processing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. AI-Enabled Neurology Devices Market: Closed-Loop and Adaptive Intelligence Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. AI-Enabled Neurology Devices Market: Cloud, Edge and Hybrid AI Architectures Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. AI-Enabled Neurology Devices Market: Procurement Channel Snapshot, 2025
TABLE 76: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 77: U.S. AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 78: U.S. AI-Enabled Neurology Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 79: U.S. AI-Enabled Neurology Devices Market: Direct Hospital and Health-System Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. AI-Enabled Neurology Devices Market: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. AI-Enabled Neurology Devices Market: Group Purchasing Organization and Aggregated Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. AI-Enabled Neurology Devices Market: Distributor and Specialty Technology Integrator Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. AI-Enabled Neurology Devices Market: Direct Procurement by Neurology Practices and Diagnostic Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. AI-Enabled Neurology Devices Market: Subscription, Per-Use and Managed-Service Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. AI-Enabled Neurology Devices Market: Capital Leasing and Equipment-as-a-Service Models Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: U.S. AI-Enabled Neurology Devices Market: Research Institution and Life-Science Partnership Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: U.S. AI-Enabled Neurology Devices Market: Regional Snapshot, 2025
TABLE 88: Segment Dashboard; Definition and Scope, by Region
TABLE 89: U.S. AI-Enabled Neurology Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 90: U.S. AI-Enabled Neurology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 91: West Region U.S. AI-Enabled Neurology Devices Market: Regional Overview and Trends
TABLE 92: West Region U.S. AI-Enabled Neurology Devices Market: Key Manufacturers, Innovation Hubs and Procurement Ecosystem
TABLE 93: West Region U.S. AI-Enabled Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 96: West Region U.S. AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 97: West Region U.S. AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 98: West Region U.S. AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 99: California AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 100: California AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 101: California AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 102: California AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 103: California AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 104: Washington AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 105: Washington AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 106: Washington AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 107: Washington AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 108: Washington AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 109: Arizona AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 110: Arizona AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 111: Arizona AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 112: Arizona AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 113: Arizona AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 114: Colorado AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 115: Colorado AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 116: Colorado AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 117: Colorado AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 118: Colorado AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 119: Oregon AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 120: Oregon AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 121: Oregon AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 122: Oregon AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 123: Oregon AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 124: Utah AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 125: Utah AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 126: Utah AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 127: Utah AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 128: Utah AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 129: Nevada AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 130: Nevada AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 131: Nevada AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 132: Nevada AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 133: Nevada AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 134: New Mexico AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 135: New Mexico AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 136: New Mexico AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 137: New Mexico AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 138: New Mexico AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 139: Idaho AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 140: Idaho AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 141: Idaho AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 142: Idaho AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 143: Idaho AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 144: Montana AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 145: Montana AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 146: Montana AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 147: Montana AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 148: Montana AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 149: Wyoming AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 150: Wyoming AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 151: Wyoming AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 152: Wyoming AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 153: Wyoming AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 154: Alaska AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 155: Alaska AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 156: Alaska AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 157: Alaska AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 158: Alaska AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 159: Hawaii AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 160: Hawaii AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 161: Hawaii AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 162: Hawaii AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 163: Hawaii AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 164: Northeast Region U.S. AI-Enabled Neurology Devices Market: Regional Overview and Trends
TABLE 165: Northeast Region U.S. AI-Enabled Neurology Devices Market: Key Manufacturers, Innovation Hubs and Procurement Ecosystem
TABLE 166: Northeast Region U.S. AI-Enabled Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 167: Northeast Region U.S. AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 168: Northeast Region U.S. AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 169: Northeast Region U.S. AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 170: Northeast Region U.S. AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 171: Northeast Region U.S. AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 172: New York AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 173: New York AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 174: New York AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 175: New York AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 176: New York AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 177: Massachusetts AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 178: Massachusetts AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 179: Massachusetts AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 180: Massachusetts AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 181: Massachusetts AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 182: New Jersey AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 183: New Jersey AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 184: New Jersey AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 185: New Jersey AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 186: New Jersey AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 187: Pennsylvania AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 188: Pennsylvania AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 189: Pennsylvania AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 190: Pennsylvania AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 191: Pennsylvania AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 192: Connecticut AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 193: Connecticut AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 194: Connecticut AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 195: Connecticut AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 196: Connecticut AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 197: Maine AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 198: Maine AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 199: Maine AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 200: Maine AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 201: Maine AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 202: Vermont AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 203: Vermont AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 204: Vermont AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 205: Vermont AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 206: Vermont AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 207: New Hampshire AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 208: New Hampshire AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 209: New Hampshire AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 210: New Hampshire AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 211: New Hampshire AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 212: Rhode Island AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 213: Rhode Island AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 214: Rhode Island AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 215: Rhode Island AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 216: Rhode Island AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 217: Delaware AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 218: Delaware AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 219: Delaware AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 220: Delaware AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 221: Delaware AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 222: South Region U.S. AI-Enabled Neurology Devices Market: Regional Overview and Trends
TABLE 223: South Region U.S. AI-Enabled Neurology Devices Market: Key Manufacturers, Innovation Hubs and Procurement Ecosystem
TABLE 224: South Region U.S. AI-Enabled Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 225: South Region U.S. AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 226: South Region U.S. AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 227: South Region U.S. AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 228: South Region U.S. AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 229: South Region U.S. AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 230: Texas AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 231: Texas AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 232: Texas AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 233: Texas AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 234: Texas AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 235: Florida AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 236: Florida AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 237: Florida AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 238: Florida AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 239: Florida AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 240: Georgia AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 241: Georgia AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 242: Georgia AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 243: Georgia AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 244: Georgia AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 245: North Carolina AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 246: North Carolina AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 247: North Carolina AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 248: North Carolina AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 249: North Carolina AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 250: Tennessee AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 251: Tennessee AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 252: Tennessee AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 253: Tennessee AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 254: Tennessee AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 255: South Carolina AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 256: South Carolina AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 257: South Carolina AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 258: South Carolina AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 259: South Carolina AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 260: Alabama AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 261: Alabama AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 262: Alabama AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 263: Alabama AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 264: Alabama AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 265: Mississippi AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 266: Mississippi AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 267: Mississippi AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 268: Mississippi AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 269: Mississippi AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 270: Louisiana AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 271: Louisiana AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 272: Louisiana AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 273: Louisiana AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 274: Louisiana AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 275: Arkansas AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 276: Arkansas AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 277: Arkansas AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 278: Arkansas AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 279: Arkansas AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 280: Kentucky AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 281: Kentucky AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 282: Kentucky AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 283: Kentucky AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 284: Kentucky AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 285: Oklahoma AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 286: Oklahoma AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 287: Oklahoma AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 288: Oklahoma AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 289: Oklahoma AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 290: Virginia AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 291: Virginia AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 292: Virginia AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 293: Virginia AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 294: Virginia AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 295: Maryland AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 296: Maryland AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 297: Maryland AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 298: Maryland AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 299: Maryland AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 300: West Virginia AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 301: West Virginia AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 302: West Virginia AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 303: West Virginia AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 304: West Virginia AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 305: Midwest Region U.S. AI-Enabled Neurology Devices Market: Regional Overview and Trends
TABLE 306: Midwest Region U.S. AI-Enabled Neurology Devices Market: Key Manufacturers, Innovation Hubs and Procurement Ecosystem
TABLE 307: Midwest Region U.S. AI-Enabled Neurology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 308: Midwest Region U.S. AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 309: Midwest Region U.S. AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 310: Midwest Region U.S. AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 311: Midwest Region U.S. AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 312: Midwest Region U.S. AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 313: Illinois AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 314: Illinois AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 315: Illinois AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 316: Illinois AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 317: Illinois AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 318: Ohio AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 319: Ohio AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 320: Ohio AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 321: Ohio AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 322: Ohio AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 323: Michigan AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 324: Michigan AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 325: Michigan AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 326: Michigan AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 327: Michigan AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 328: Minnesota AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 329: Minnesota AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 330: Minnesota AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 331: Minnesota AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 332: Minnesota AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 333: Indiana AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 334: Indiana AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 335: Indiana AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 336: Indiana AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 337: Indiana AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 338: Wisconsin AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 339: Wisconsin AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 340: Wisconsin AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 341: Wisconsin AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 342: Wisconsin AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 343: Missouri AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 344: Missouri AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 345: Missouri AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 346: Missouri AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 347: Missouri AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 348: Iowa AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 349: Iowa AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 350: Iowa AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 351: Iowa AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 352: Iowa AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 353: Kansas AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 354: Kansas AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 355: Kansas AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 356: Kansas AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 357: Kansas AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 358: Nebraska AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 359: Nebraska AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 360: Nebraska AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 361: Nebraska AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 362: Nebraska AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 363: North Dakota AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 364: North Dakota AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 365: North Dakota AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 366: North Dakota AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 367: North Dakota AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 368: South Dakota AI-Enabled Neurology Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 369: South Dakota AI-Enabled Neurology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 370: South Dakota AI-Enabled Neurology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 371: South Dakota AI-Enabled Neurology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 372: South Dakota AI-Enabled Neurology Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 373: U.S. AI-Enabled Neurology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 374: U.S. AI-Enabled Neurology Devices Market: Key Company Market Share Analysis, 2025
TABLE 375: U.S. AI-Enabled Neurology Devices Market: Competitive Benchmarking Analysis
TABLE 376: U.S. AI-Enabled Neurology Devices Market: Company Positioning Matrix
TABLE 377: U.S. AI-Enabled Neurology Devices Market: Product Portfolio and Application Coverage Matrix
TABLE 378: U.S. AI-Enabled Neurology Devices Market: Clinical Evidence and FDA Authorization Benchmarking
TABLE 379: U.S. AI-Enabled Neurology Devices Market: Partnerships, Acquisitions and Collaboration Analysis
TABLE 380: Medtronic: Company Profile
TABLE 381: Abbott Laboratories: Company Profile
TABLE 382: Boston Scientific Corporation: Company Profile
TABLE 383: Stryker Corporation: Company Profile
TABLE 384: Penumbra, Inc.: Company Profile
TABLE 385: GE HealthCare: Company Profile
TABLE 386: Siemens Healthineers: Company Profile
TABLE 387: Philips Healthcare: Company Profile
TABLE 388: Canon Medical Systems USA: Company Profile
TABLE 389: Brainlab: Company Profile
TABLE 390: Viz.ai: Company Profile
TABLE 391: RapidAI: Company Profile
TABLE 392: Aidoc: Company Profile
TABLE 393: Avicenna.AI: Company Profile
TABLE 394: Brainomix: Company Profile
TABLE 395: Ceribell, Inc.: Company Profile
TABLE 396: Empatica: Company Profile
TABLE 397: BrainScope Company, Inc.: Company Profile
TABLE 398: Oculogica, Inc.: Company Profile
TABLE 399: NeuroPace, Inc.: Company Profile
TABLE 400: Neuronetics, Inc.: Company Profile
TABLE 401: LivaNova PLC: Company Profile
TABLE 402: ClearPoint Neuro, Inc.: Company Profile
TABLE 403: Rune Labs: Company Profile
TABLE 404: Neuro Event Labs: Company Profile
TABLE 405: U.S. AI-Enabled Neurology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 406: U.S. AI-Enabled Neurology Devices Market: Disruptive Technologies Impact Matrix
TABLE 407: U.S. AI-Enabled Neurology Devices Market: Emerging Business Trends
TABLE 408: U.S. AI-Enabled Neurology Devices Market: Business Opportunities for Startups and Existing Players
TABLE 409: U.S. AI-Enabled Neurology Devices Market: Investment Prioritization Matrix
TABLE 410: U.S. AI-Enabled Neurology Devices Market: Product and Application Opportunity Heatmap
TABLE 411: U.S. AI-Enabled Neurology Devices Market: Technology Adoption Timeline, 2026–2035
TABLE 412: U.S. AI-Enabled Neurology Devices Market: Strategic Recommendations for Neurology Device Manufacturers
TABLE 413: U.S. AI-Enabled Neurology Devices Market: Strategic Recommendations for AI and Clinical Software Developers
TABLE 414: U.S. AI-Enabled Neurology Devices Market: Strategic Recommendations for Hospitals and Integrated Health Systems
TABLE 415: U.S. AI-Enabled Neurology Devices Market: Strategic Recommendations for Stroke Centers and Neuroscience Institutes
TABLE 416: U.S. AI-Enabled Neurology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 417: U.S. AI-Enabled Neurology Devices Market: Strategic Recommendations for Distributors and Technology Integrators
TABLE 418: U.S. AI-Enabled Neurology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 419: U.S. AI-Enabled Neurology Devices Market: Go-to-Market Strategy Considerations
TABLE 420: U.S. AI-Enabled Neurology Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 421: U.S. AI-Enabled Neurology Devices Market: Clinical Evidence and Regulatory Strategy Guidance
TABLE 422: U.S. AI-Enabled Neurology Devices Market: Reimbursement and Health-Economic Evidence Strategy
TABLE 423: U.S. AI-Enabled Neurology Devices Market: Enterprise Integration and Cybersecurity Strategy
TABLE 424: U.S. AI-Enabled Neurology Devices Market: Partnership, Licensing and Acquisition Strategy
TABLE 425: U.S. AI-Enabled Neurology Devices Market: Scope Limitation
TABLE 426: U.S. AI-Enabled Neurology Devices Market: Data Use Limitation
TABLE 427: U.S. AI-Enabled Neurology Devices Market: Market Sizing and Forecasting Limitation
TABLE 428: U.S. AI-Enabled Neurology Devices Market: AI Technology and Regulatory Change Limitation
TABLE 429: U.S. AI-Enabled Neurology Devices Market: Legal Disclaimer
TABLE 430: U.S. AI-Enabled Neurology Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. AI-Enabled Neurology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Value Chain Analysis
FIGURE 4: Supply Chain Analysis
FIGURE 5: PESTEL Analysis
FIGURE 6: Porter’s Five Forces Analysis
FIGURE 7: Market Attractiveness Analysis
FIGURE 8: Market Dynamics
FIGURE 9: Innovation & Patent Landscape, 2021–2025
FIGURE 10: Clinical Workflow Economics Framework
FIGURE 11: Hospital Capital Procurement Decision Framework
FIGURE 12: AI Device Adoption Readiness Framework
FIGURE 13: FDA, Reimbursement and Enterprise AI Governance Framework
FIGURE 14: U.S. AI-Enabled Neurology Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 15: U.S. AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 16: U.S. AI-Enabled Neurology Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 17: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 18: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: AI-Enabled Neuroimaging and Stroke-Triage Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: AI-Enabled EEG and Seizure-Monitoring Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Intelligent Neuromodulation and Implantable Neurological Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: AI-Assisted Surgical Navigation and Neurointerventional Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Wearable, Digital Biomarker and Neurorehabilitation Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 25: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Stroke and Cerebrovascular Disease Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Epilepsy and Seizure Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Neurodegenerative Disease Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Movement Disorders and Tremor Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Neurosurgery, Brain Injury, Neurocritical Care and Rehabilitation Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 32: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Comprehensive Stroke Centers, Neuroscience Institutes and Academic Medical Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Neurology Practices, Epilepsy Centers, Sleep Laboratories and Diagnostic Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Ambulatory Surgery Centers and Specialized Neurosurgical Facilities Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Home Healthcare, Rehabilitation and Remote Monitoring Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 39: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Machine Learning and Deep Learning Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Computer Vision and Advanced Image Processing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Predictive Analytics and Multimodal Biosignal Processing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Closed-Loop and Adaptive Intelligence Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Cloud, Edge and Hybrid AI Architectures Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 46: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Direct Hospital and Health-System Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Group Purchasing Organization and Aggregated Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Distributor and Specialty Technology Integrator Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Direct Procurement by Neurology Practices and Diagnostic Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Subscription, Per-Use and Managed-Service Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Capital Leasing and Equipment-as-a-Service Models Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: Research Institution and Life-Science Partnership Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 56: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: West Region U.S. AI-Enabled Neurology Devices Market Share and Leading Players, 2025
FIGURE 58: West Region Market Share Analysis by State, 2025
FIGURE 59: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: California AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Washington AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Arizona AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Colorado AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Oregon AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Utah AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Nevada AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: New Mexico AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Idaho AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Montana AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Wyoming AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Alaska AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Hawaii AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Northeast Region U.S. AI-Enabled Neurology Devices Market Share and Leading Players, 2025
FIGURE 74: Northeast Region Market Share Analysis by State, 2025
FIGURE 75: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: New York AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Massachusetts AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New Jersey AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Pennsylvania AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Connecticut AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Maine AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Vermont AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: New Hampshire AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Rhode Island AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Delaware AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: South Region U.S. AI-Enabled Neurology Devices Market Share and Leading Players, 2025
FIGURE 87: South Region Market Share Analysis by State, 2025
FIGURE 88: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Texas AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Florida AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Georgia AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: North Carolina AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Tennessee AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: South Carolina AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Alabama AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Mississippi AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Louisiana AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Arkansas AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Kentucky AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Oklahoma AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Virginia AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Maryland AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: West Virginia AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Midwest Region U.S. AI-Enabled Neurology Devices Market Share and Leading Players, 2025
FIGURE 105: Midwest Region Market Share Analysis by State, 2025
FIGURE 106: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Illinois AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Ohio AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Michigan AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Minnesota AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Indiana AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Wisconsin AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Missouri AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Iowa AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Kansas AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Nebraska AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: North Dakota AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: South Dakota AI-Enabled Neurology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 120: Company Positioning Matrix
FIGURE 121: Key Player Product Portfolio and Application Benchmarking
FIGURE 122: Clinical Evidence and FDA Authorization Benchmarking
FIGURE 123: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 124: AI-Enabled Neurology Device Innovation Roadmap
FIGURE 125: AI-Enabled Stroke Detection and Triage Adoption Roadmap
FIGURE 126: Rapid EEG and Seizure-Monitoring Opportunity Map
FIGURE 127: Adaptive Neuromodulation Technology Roadmap
FIGURE 128: Digital Biomarker and Remote Neurology Growth Roadmap
FIGURE 129: AI-Assisted Neurosurgical Navigation Opportunity Map
FIGURE 130: Brain-Computer Interface Development Roadmap
FIGURE 131: Future Market Scenario Analysis, 2026–2035
FIGURE 132: Disruptive Technologies Impact Matrix
FIGURE 133: Emerging Business Trends Matrix
FIGURE 134: Product and Application Opportunity Heatmap
FIGURE 135: Investment Prioritization Matrix
FIGURE 136: Strategic Growth Roadmap for U.S. AI-Enabled Neurology Device Companies
FIGURE 137: Go-to-Market Strategy Framework
FIGURE 138: Clinical Evidence, Reimbursement and Regulatory Strategy Framework
FIGURE 139: Product Positioning and Portfolio Expansion Framework
FIGURE 140: Report Scope and Disclaimer Framework